Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma.
Gulam Mustafa HasanM D Imtaiyaz HassanSukhwinder Singh SohalAnas ShamsiManzar AlamPublished in: ACS omega (2023)
Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, and angiogenesis by regulating signaling pathways. These molecules affect several cellular signaling cascades, including p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, and AKT/PI3K, and are thus implicated in the therapeutic management of cancers. This review aims to describe the bioactive compounds and small-molecule inhibitors, their anticancer action, and targeting cellular signaling cascades in NSCLC. We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors.
Keyphrases
- signaling pathway
- small molecule
- small cell lung cancer
- pi k akt
- advanced non small cell lung cancer
- cell proliferation
- epithelial mesenchymal transition
- induced apoptosis
- cell cycle arrest
- protein protein
- brain metastases
- oxidative stress
- single cell
- cancer therapy
- epidermal growth factor receptor
- stem cells
- papillary thyroid
- endoplasmic reticulum stress
- endothelial cells
- lps induced
- drinking water
- nuclear factor
- drug induced
- squamous cell
- wild type
- toll like receptor
- childhood cancer
- tyrosine kinase